Figures (1)  Tables (7)

    • Figure 1. 

      Survival curves of patients in this study. (a) PFS survival curve of the overall population with mPFS of 5.8 months (95% CI = 4.883−6.717). (b) OS survival curve of the overall population with mOS of 11 months (95% CI = 9.355−13.505). (c) PFS survival curves of the A + AG regimen group and the AG regimen group (p = 0.003). (d) OS survival curves of the A + AG regimen group and AG regimen group (p = 0.001). (e) OS survival curves according to the ECOG score. (f) OS survival curves according to the metastasis site.

    • Clinical characteristics A + AG group
      (n = 32)      		 AG group
      (n = 39)      		 p-value
      Gender 0.551
      Male 20 (62.5%) 27 (69.2%)
      Female 12 (37.5%) 12 (30.8%)
      Age (years, $ \overline{x}\pm s $ ) 64.0 ± 10.0 66.9 ± 8.7 0.199
      Smoking history 10 (31.3%) 10 (25.6%) 0.601
      Drinking history 11 (34.4%) 15 (38.5%) 0.722
      Past medical history
      Hypertension 14 (43.8%) 15 (38.5%) 0.652
      Diabetes 10 (31.3%) 13 (33.3%) 0.852
      BMI (kg/m2), $\overline{x}\pm s $ ) 22.6 ± 2.5 21.4 ± 2.8 0.089
      ECOG score 0.801
      0−1 19 (59.4%) 22 (56.4%)
      2 13 (40.6%) 17 (43.6%)
      Pathological type 0.782
      Adenocarcinoma 28 (87.5%) 36 (92.3%)
      Other types 4 (12.5%) 3 (7.7%)
      Metastatic site
      Liver 25 (78.1%) 23 (59.0%) 0.086
      Lung 10 (31.3%) 15 (38.5%) 0.527
      Peritoneum 4 (12.5%) 9 (23.1%) 0.252
      Lymph node 17 (53.1%) 21 (53.8%) 0.952
      CA19-9 (U/ml) 0.307
      ≤ 27 9 (28.1%) 7 (21.9%)
      > 27 23 (71.9%) 32 (78.1%)
      TR (u/ml) 0.185
      ≤ 4 12 (37.5%) 9 (23.1%)
      > 4 20 (62.5%) 30 (76.9%)
      The figures in parentheses indicate the proportion of patients as percentages.

      Table 1. 

      Patient characteristics.

    • Tumor response A + AG group (n = 32) AG group (n = 39) p-value
      CR 0 0
      PR 4 2
      SD 24 27
      PD 4 10
      ORR 4 (12.5%) 2 (5.1%) 0.399
      DCR 28 (87.5%) 29 (74.4%) 0.233

      Table 2. 

      Comparison of tumor response status between the two groups.

    • Clinical features Univariate analysis Multivariate analysis
      HR 95% CI p HR 95% CI p
      Gender
      Male 1.00
      Female 0.70 0.34−1.44 0.331
      Age 1.03 0.99−1.07 0.141
      BMI (kg/m2 ) 1.09 0.96−1.24 0.205
      Hypertension
      True 1.000
      False 0.909 0.467−1.769 0.778
      ECOG score 1.24 0.64−2.38 0.526
      Pathological type
      Adenocarcinoma 1.00 1.00
      Other types 10.20 2.24−46.53 0.003 1.07 0.18−6.52 0.943
      Lymph node metastasis
      True 1.00
      False 0.72 0.37−1.42 0.342
      Liver metastasis
      True 1.00
      False 1.28 0.67−2.46 0.461
      Pulmonary metastasis
      True 1.00
      False 0.79 0.40−1.55 0.492
      Peritoneal metastasis
      True 1.00
      False 0.70 0.32−1.53 0.372
      CA199 level
      Negative 1.00
      Positive 1.97 0.85−4.58 0.113
      TR 0.96 0.85−1.07 0.457

      Table 3. 

      Univariate and multivariate analysis of factors influencing PFS in patients in the AG regimen group.

    • Clinical features Univariate analysis Multivariate analysis
      HR 95% CI p HR 95% CI p
      Gender
      Male 1.00
      Female 1.30 0.62−2.73 0.487
      Age 1.00 0.96−1.05 0.981
      BMI (kg/m2 ) 1.01 0.90−1.14 0.858
      Hypertension
      True 1.00
      False 0.59 0.28−1.22 0.156
      ECOG score 1.13 0.56−2.26 0.737
      Pathological type
      Adenocarcinoma 1.00 1.00
      Other types 11.28 2.45−51.98 0.002 3.34 0.51−21.82 0.208
      Lymph node metastasis
      True 1.00
      False 0.88 0.44−1.77 0.719
      Liver metastasis
      True 1.00
      False 0.64 0.30−1.37 0.253
      Pulmonary metastasis
      True 1.00
      False 0.88 0.44−1.78 0.725
      Peritoneal metastasis
      True 1.00
      False 1.35 0.58−3.14 0.482
      CA199 level
      Negative 1.00 1.00
      Positive 2.95 1.18−7.35 0.020 3.34 1.12−10.22 0.031
      TR 1.05 0.93−1.18 0.461

      Table 4. 

      Univariate and multivariate analysis of factors influencing OS in patients in the AG regimen group.

    • Clinical features Univariate analysis Multivariate analysis
      HR 95% CI p HR 95% CI p
      Gender
      Male 1.00
      Female 0.72 0.35−1.50 0.383
      Age 1.00 0.96−1.04 0.941
      BMI (kg/m2 ) 0.98 0.85−1.14 0.789
      Hypertension
      True 1.00
      False 0.79 0.38−1.64 0.521
      ECOG score 0.97 0.47−2.00 0.934
      Pathological type
      Adenocarcinoma 1.00
      Other types 1.27 0.43−3.70 0.664
      Lymph node metastasis
      True 1.00
      False 0.98 0.48−1.99 0.950
      Liver metastasis
      True 1.00
      False 1.92 0.78−4.72 0.155
      Pulmonary metastasis
      True 1.00
      False 1.40 0.62−3.18 0.424
      Peritoneal metastasis
      True 1.00
      False 0.78 0.27−2.26 0.649
      CA199 level
      Negative 1.00 1.00
      Positive 2.31 0.93−5.77 0.073 2.39 0.94−6.06 0.067
      TR 1.17 1.03−1.33 0.014 1.11 0.97−1.28 0.128

      Table 5. 

      Univariate and multivariate analysis of factors influencing PFS in patients in the A + AG regimen group.

    • Clinical features Univariate analysis Multivariate analysis
      HR 95% CI p HR 95% CI p
      Gender
      Male 1.00
      Female 1.34 0.55−3.25 0.521
      Age 1.06 0.96−1.05 0.056 1.06 0.98−1.15 0.170
      BMI (kg/m2 ) 1.07 0.88−1.31 0.475
      Hypertension
      True 1.00 1.00
      False 0.37 0.14−1.00 0.050 0.84 0.24−2.92 0.789
      ECOG score 0.78 0.31−1.95 0.588
      Pathological type
      Adenocarcinoma 1.00
      Other types 1.38 0.39−4.89 0.614
      Lymph node metastasis
      True 1.00
      False 1.18 0.49−2.87 0.709
      Liver metastasis
      True 1.00
      False 0.56 0.18−1.75 0.321
      Pulmonary metastasis
      True 1.00
      False 0.86 0.35−2.10 0.735
      Peritoneal metastasis
      True 1.00
      False 1.48 0.34−6.47 0.605
      CA199 level
      Negative 1.00
      Positive 1.83 0.67−5.05 0.242
      TR 1.18 1.01−1.38 0.035 1.07 0.88−1.31 0.496

      Table 6. 

      Univariate and multivariate analysis of factors influencing OS in patients in the A + AG regimen group.

    • Grade III adverse reactions Grade III/IV adverse reactions
      Group A + AG Group AG p value Group A + AG Group AG p value
      Leucopenia 17 (53.2%) 23 (58.9%) 0.800 13 (40.6%) 12 (30.8%) 0.387
      Decreased hemoglobin 17 (53.1%) 16 (41.1%) 0.437 4 (12.5%) 7 (17.9%) 0.763
      Thrombocytopenia 15 (46.9%) 21 (53.9%) 0.729 11 (34.4%) 8 (20.5%) 0.189
      Hypoalbuminemia 13 (40.6%) 20 (51.3%) 0.511 8 (25.0%) 7 (17.9%) 0.469
      Diarrhea 19 (59.3%) 18 (46.1%) 0.384 2 (6.3%) 1 (2.6%) 0.585
      Pleural and abdominal fluid 8 (25.0%) 3 (7.7%) 0.094 3 (9.4%) 5 (12.8%) 0.936
      Nausea and vomiting 18 (56.2%) 26 (66.7%) 0.513 7 (21.9%) 6 (15.4%) 0.482
      Fatigue and poor appetite 24 (75.0%) 29 (74.4%) 1.000 5 (15.6%) 3 (7.7%) 0.500
      Hepatic dysfunction 11 (34.4%) 13 (33.3%) 1.000 9 (28.1%) 4 (10.3%) 0.053
      Hemorrhage 3 (9.4%) 1 (2.6%) 0.471 1 (3.1%) 0 0.921
      Hypertension 8 (25.0%) 5 (12.8%) 0.312 14 (43.8%) 11 (28.2%) 0.172
      Hand-foot syndrome 6 (18.7%) 5 (12.8%) 0.153 2 (6.3%) 0 0.200
      Hyperlipidemia 10 (31.2%) 10 (25.6%) 0.797 6 (18.8%) 3 (7.7%) 0.301
      Proteinuria 16 (50.0%) 17 (43.6%) 0.764 4 (12.5%) 2 (5.1%) 0.399

      Table 7. 

      Comparison of adverse reactions between the two groups.